Wakefulness-promoting agent

A wakefulness-promoting agent (or wakefulness-promoting drug), also known as a eugeroic (originally "eugrégorique" or "eugregoric"),[1] is a type of drug which specifically improves wakefulness and alertness.[2][3] They are used mainly in the treatment of sleeping disorders, excessive daytime sleepiness and narcolepsy.[2][3] They are also used to counteract fatigue and lethargy and to increase motivation and productivity. Wakefulness-promoting agents are said to have a low or very low addictive potential.[2][3]

The prototypical eugeroic is modafinil, and other drugs include adrafinil and armodafinil. Modafinil and armodafinil have been found to act as selective, weak, atypical dopamine reuptake inhibitors.[2][3] Adrafinil is a prodrug of modafinil, and hence also acts in this way.

Examples

The chemical structure of modafinil, the prototypical drug of this class.

Marketed

Discontinued

Never marketed

See also

Categories

<a class='CategoryTreeLabel CategoryTreeLabelNs14 CategoryTreeLabelCategory' href='/wiki/Category:Drug_classes_defined_by_psychological_effects'>Drug classes defined by psychological effects</a>
<a class='CategoryTreeLabel CategoryTreeLabelNs14 CategoryTreeLabelCategory' href='/wiki/Category:Drugs_by_psychological_effects'>Drugs by psychological effects</a>
<a class='CategoryTreeLabel CategoryTreeLabelNs14 CategoryTreeLabelCategory' href='/wiki/Category:Psychoactive_drugs'>Psychoactive drugs</a>

References

  1. Milgram, Norton W.; Callahan, Heather; Siwak, Christina (2006). "Adrafinil: A Novel Vigilance Promoting Agent". CNS Drug Reviews. 5 (3): 193–212. doi:10.1111/j.1527-3458.1999.tb00100.x. ISSN 1080-563X.
  2. 1 2 3 4 "Provigil: Prescribing information" (PDF). United States Food and Drug Administration. Cephalon, Inc. January 2015. Retrieved 16 August 2015.
  3. 1 2 3 4 "Nuvigil: Prescribing information" (PDF). United States Food and Drug Administration. Cephalon, Inc. April 2015. Retrieved 16 August 2015.

This article is issued from Wikipedia - version of the 11/29/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.